Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets

Table 3 Demographic data for study subjects

Sample	Age (Range in yrs.)	Diagnosis	Duration (years)	Current Meds	Previous Treatments	Past Med History
VL1009B	60–69	Vitiligo	10	None	topical and oral steroid	HTN
VL1010B	50–59	Vitiligo	2	None	steroid (1.5 yrs ago)	hypothyroid
VL1016B^a	70–79	Vitiligo	50	ASA, atenolol, lipitor, detrol LA	Methoxsalen (45–50 yrs. ago), none currently	None
VL1017B^a	30–39	Vitiligo	10	PABA, vitamin B12, trazodone and other antianxiety med	light treatment (6 yrs. ago), Vit B12 injection	None
VL1018B^a	30–39	Vitiligo	12	None	None	None
VL1019B^a	30–39	Vitiligo	26	None	None	Factor V disorder
VL1020B	60–69	Vitiligo	30	None	None	None
VL1021B	60–69	Vitiligo	>20	sunblock	benoquin (depigmentation agent)	rosacea (10yrs ago), osteoarthritis, SCC (10yrs ago)
NL1001B	50–59	No disease	none	none	none	none
NL1004B	30–39	No disease	none	none	none	none
NL1013B	30–39	No disease	none	none	none	none
NL1014B	40–49	No disease	none	none	none	none
NL1020B	50–59	No disease	none	none	none	none
NL1032B	40–49	No disease	none	none	none	none

Abbreviations: VL vitiligo, NL normal, B blood, PABA para amino benzoic acid, HTN hypertension, SCC squamous cell carcinoma, ASA amino salicylic acid, LA long acting. Patients were under no systemic or topical medications for 2 months prior to sampling. ^aStarred samples are shared between our previous skin and the present blood analyses. Gender and ethnicity details are withheld to protect patient privacy. While the healthy controls were 100% females, the female to male ratio in vitiligo patients is 6.2: 3.8. Ethnicity distribution among healthy controls is 67% African American, 17% Caucasian and 17% Asian and among VL patients 50% Caucasians, 25% Hispanics, 12.5% Asian and 12.5% African

ISSN: 1471-2164